About IndiDX
IndiDX is a Healthcare company based in Boulder (United States) founded in 2005, and was acquired by Biodesix in July 2018. Blood-based diagnostics for oncology. IndiDX has raised $82.81 million across 6 funding rounds from investors including Biodesix, Baird Capital and InterWest. The company has 17 employees. The company was acqui-hired. Its focus areas include Life Sciences, Oncology, In-Vitro Diagnostic Tests and Lung cancer. Its legal entity is Integrated Diagnostics Inc. Its competitors include Biodesix, Broncus and OncoCyte; 3 of its 3 listed competitors have raised funding.
Company details
Integrated Diagnostics (Indi) is developing blood based diagnostics for oncology by following a systems biology based approach. Its flagship product, the Xpresys Lung test claims to detect the molecular changes in proteins associated with the presence of lung cancer and provide a non-invasive assessment of pulmonary nodules. Patient blood is analyzed by mass spectrometry that provides specific detection of target proteins. When combined with clinical assessment, Xpresys Lung claims to be able to help reduce unnecessary invasive procedures
- Headquarters Boulder, United States
- Employees 17
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Website indidx.com
- Social LinkedIn
- Acquired by Biodesix (Jul 2018)
- Legal Name Integrated Diagnostics Inc
Funding Insights of IndiDX
IndiDX has successfully raised a total of $82.81M across 6 strategic funding rounds. The most recent funding activity was a Series C round of $6.1 million completed in December 2016. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $82.81M
- Total Rounds 6
- Last Round Series C — $6.1M
- First Round $5M
(Jun 2005)
- Investors Count 6
All 6 funding rounds of IndiDX with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec 2016 | $6.1M | Series C | – | Baird Capital, InterWest Partners | – |
| May 2014 | $31.71M | Series B | – | Baird Capital, Wellcome Trust | – |
| Apr 2014 | $17M | Debt – Conventional | – | – | |
| Jul 2010 | $10M | Series A | – | – | – |
| Sep 2009 | $30M | Series A | – | Wellcome Trust, Dievini | – |
| Jun 2005 | $5M | Series A | – | – |
7 investors in total: 7 institutional.
Investors in IndiDX
IndiDX has secured backing from 7 investors, including venture fund and institutional investors. Prominent investors backing the company include Biodesix, Baird Capital and InterWest.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Global private equity and venture capital investments in B2B Tech & Services companies. | bairdcapital.com | |||
Early-stage investing in IT and healthcare ventures. | interwest.com | |||
| lsafunding.com | ||||
Investments are made in life and health sciences companies. | dievini.de | Germany | ||
Venture capital services are offered for early-stage biotech companies. | acceleratorlsp.com | Seattle, United States | ||
Wellcome is a global charitable foundation focused on health research. | wellcome.ac.uk | London, United Kingdom | ||
Cancer detection diagnostics assays are developed and offered. | 2005 | biodesix.com | Boulder, United States |
Investor details for IndiDX
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of IndiDX
4 dated milestones of IndiDX across 13 years, from founding to its latest funding, stage changes and deals.
- Founded IndiDX is founded.
- Funding First funding round of $5.0M.
- Funding Latest funding round, Series C, of $6.1M.
- Exit Acquired by Biodesix.
Competitors of IndiDX
IndiDX has 3 listed competitors in our database, 3 of them funded. They include Biodesix, Broncus and OncoCyte.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| biodesix.com | 2005 | Boulder, United States | $200.16M | 217 | Cancer detection diagnostics assays are developed and offered. | |
| broncus.com | 1997 | San Jose, United States | $44.5M | 36 | Minimally invasive technologies for lung disease treatment are developed. | |
| oncocyte.com | 2009 | Irvine, United States | $15.35M | 76 | Non-invasive diagnostic test solutions for cancer treatment are developed. |
Detailed competitors of IndiDX
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Oncology
3 companies that operate in the same segment as IndiDX (Oncology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Indidx
Complete news archive for IndiDX
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about IndiDX
IndiDX was founded in 2005.
IndiDX is headquartered in Boulder, United States. It is registered at Boulder, Colorado, United States.
IndiDX is a funded company, having raised a total of $82.81M across 6 funding rounds to date. The company's 1st funding round was a Series A of $5M, raised on Jun 2005.
IndiDX has 17 employees.
Integrated Diagnostics (Indi) is developing blood based diagnostics for oncology by following a systems biology based approach. Its flagship product, the Xpresys Lung test claims to detect the molecular changes in proteins associated with the presence of lung cancer and provide a non-invasive assessment of pulmonary nodules. Patient blood is analyzed by mass spectrometry that provides specific detection of target proteins. When combined with clinical assessment, Xpresys Lung claims to be able to help reduce unnecessary invasive procedures.
IndiDX has 7 investors. Key investors include Biodesix, Baird Capital, InterWest, Wellcome, and Life Sciences Alternative Funding.
IndiDX operates through Integrated Diagnostics Inc.
Yes. IndiDX was acquired by Biodesix in July 2018.